Tarsus Pharmaceuticals (TARS) Insider Goldberg Buys 2,417 Shares

Andrew Goldberg recently bought 3,837 shares of Tarsus Pharmaceuticals, Inc. (NasdaqGS: TARS) on June 25, 2026. The purchase price wasn't disclosed, and the transaction wasn't part of a pre-planned trading program.

Insider Buying and Selling at Tarsus Pharmaceuticals, Inc.

Several insiders made purchases on June 25, 2026. David Pyott bought 3,223 shares, William Link acquired 3,837 shares, and Scott Morrison purchased 2,417 shares. None of these transactions were planned, and the purchase prices were not disclosed.

Other Institutional Activity in Tarsus Pharmaceuticals

Deep Track Capital, LP increased its holdings by 595,966 shares, ending with 3.6 million shares valued at about $252.54 million, marking a 19.8% increase. BlackRock, Inc. trimmed its position by 237,945 shares, holding 3,552,612 shares worth approximately $249.22 million, a 6.3% decrease. RTW Investments, LP added 10,705 shares, bringing its total to 3,346,025 shares valued at $234.72 million, a modest 0.3% increase. Janus Henderson Group PLC boosted its stake by 310,638 shares, now holding 2,240,963 shares valued at $157.22 million, reflecting a 16.1% increase.

Tarsus Pharmaceuticals, Inc. Stock Down 21.6%

Shares of Tarsus Pharmaceuticals traded around $62.92 on Tuesday. The company has a market cap of about $2.71 billion and a forward P/E ratio of 21.95. Its beta is 0.506, indicating lower volatility compared to the market. The stock's 52-week range is between $38.51 and $85.25, with a 50-day moving average of $62.45 and a 200-day moving average of $68.45. Tarsus has a strong liquidity position with a current ratio of 3.74 and a quick ratio of 3.53, while its debt-to-equity ratio stands at 25.41.

Analysts Set New Price Targets

On May 4, 2026, HC Wainwright & Co. reiterated its 'buy' rating with a price target of $88. Oppenheimer maintained a 'buy' rating with a target of $105 on February 25, 2026. Guggenheim also maintained a 'buy' rating with a $90 target. The consensus among nine analysts is a 'buy' rating with an average target price of $94.11.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., based in Irvine, California, is a biopharmaceutical company focused on developing treatments for eye care. It offers XDEMVY, a solution for demodex blepharitis, and is working on other therapeutic candidates like TP-04 for ocular rosacea and TP-05 for Lyme disease prevention. The company operates within the healthcare sector, specifically in biotechnology, and is led by CEO Dr. Bobak R. Azamian.

Bottom Line

Andrew Goldberg's purchase of Tarsus Pharmaceuticals shares could signal confidence in the company's prospects. However, it's important to note that insider transactions are just one of many factors investors consider. Tarsus Pharmaceuticals continues to be a subject of interest, with analysts maintaining positive ratings and setting ambitious price targets. As always, investors should consider multiple sources of information and analysis before making investment decisions.